QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:VYNE

VYNE Therapeutics (VYNE) Stock Forecast, Price & News

$5.63
-0.32 (-5.38%)
(As of 06/8/2023 ET)
Compare
Today's Range
$5.61
$5.99
50-Day Range
$2.58
$8.66
52-Week Range
$1.99
$9.90
Volume
8,639 shs
Average Volume
458,558 shs
Market Capitalization
$18.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

VYNE Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
228.6% Upside
$18.50 Price Target
Short Interest
Healthy
2.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$74,600 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($5.61) to ($2.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

406th out of 986 stocks

Pharmaceutical Preparations Industry

182nd out of 473 stocks


VYNE stock logo

About VYNE Therapeutics (NASDAQ:VYNE) Stock

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded on October 21, and is headquartered in Bridgewater, NJ.

Receive VYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYNE Stock News Headlines

VYNE Therapeutics (NASDAQ: VYNE)
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Recap: VYNE Therapeutics Q1 Earnings
See More Headlines

VYNE Price History

VYNE Company Calendar

Last Earnings
5/11/2023
Today
6/08/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYNE
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.50
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+228.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-23,210,000.00
Net Margins
-8,417.59%
Pretax Margin
-7,751.26%

Debt

Sales & Book Value

Annual Sales
$480,000.00
Book Value
$9.67 per share

Miscellaneous

Free Float
3,140,000
Market Cap
$18.41 million
Optionable
Not Optionable
Beta
1.60

Key Executives

  • David Domzalski
    President, Chief Executive Officer & Director
  • Tyler Zeronda
    Chief Financial Officer & Treasurer
  • Iain A. Stuart
    Chief Scientific Officer
  • Mutya Harsch
    Secretary, Chief Legal Officer & General Counsel













VYNE Stock - Frequently Asked Questions

Should I buy or sell VYNE Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE shares.
View VYNE analyst ratings
or view top-rated stocks.

What is VYNE Therapeutics' stock price forecast for 2023?

2 analysts have issued 12-month price targets for VYNE Therapeutics' stock. Their VYNE share price forecasts range from $9.00 to $28.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 228.6% from the stock's current price.
View analysts price targets for VYNE
or view top-rated stocks among Wall Street analysts.

How have VYNE shares performed in 2023?

VYNE Therapeutics' stock was trading at $2.70 at the beginning of 2023. Since then, VYNE shares have increased by 108.5% and is now trading at $5.63.
View the best growth stocks for 2023 here
.

Are investors shorting VYNE Therapeutics?

VYNE Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 91,900 shares, a decrease of 55.6% from the April 30th total of 206,800 shares. Based on an average daily volume of 702,800 shares, the short-interest ratio is presently 0.1 days. Approximately 2.9% of the company's shares are short sold.
View VYNE Therapeutics' Short Interest
.

When is VYNE Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our VYNE earnings forecast
.

How were VYNE Therapeutics' earnings last quarter?

VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its earnings results on Thursday, May, 11th. The company reported ($1.74) earnings per share for the quarter, topping analysts' consensus estimates of ($2.50) by $0.76. The company earned $0.10 million during the quarter. VYNE Therapeutics had a negative net margin of 8,417.59% and a negative trailing twelve-month return on equity of 84.52%.

When did VYNE Therapeutics' stock split?

Shares of VYNE Therapeutics reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of VYNE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

What is VYNE Therapeutics' stock symbol?

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

Who are VYNE Therapeutics' major shareholders?

VYNE Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DSC Advisors L.P. (3.52%), BlackRock Inc. (1.50%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.76%), Staley Capital Advisers Inc. (0.72%) and Susquehanna International Group LLP (0.55%). Insiders that own company stock include Andrew Saik, David Domzalski, Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of VYNE Therapeutics?

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VYNE Therapeutics' stock price today?

One share of VYNE stock can currently be purchased for approximately $5.63.

How much money does VYNE Therapeutics make?

VYNE Therapeutics (NASDAQ:VYNE) has a market capitalization of $18.41 million and generates $480,000.00 in revenue each year. The company earns $-23,210,000.00 in net income (profit) each year or ($10.6455) on an earnings per share basis.

How can I contact VYNE Therapeutics?

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The official website for the company is vynetherapeutics.com. The company can be reached via phone at (800) 755-7936 or via email at jallaire@lifesciadvisors.com.

This page (NASDAQ:VYNE) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -